Pfizer Prospects Garner Mixed Sentiment From Analysts: ‘Finally, The Pivot Investors Have Been Waiting For’
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs work.
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance reaffirms $4 billion sales target for 2024.
Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?
Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
Wellcare, The Medicare Business Of Centene Corp And Wellvana Announce Partnership To Expand Patient-Centered Primary Care For Benefit Of Medicare Advantage Members In Georgia, Tennessee And Texas
Wellcare, the Medicare business of Centene Corporation (NYSE:CNC), and Wellvana, a value-based care physician enablement company, today announced a multi-year partnership that seeks to expand affordable,
ASLAN Pharmaceuticals Announces Expansion Of Its Collaboration With Zenyaku To Investigate The Biology Underlying Differential Effects Of Eblasakimab Compared To Other Biologics
New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will deepen understanding of
Elevai Biosciences Highlights Preclinical Data Showing Potential Of In-Licensed Asset “EL-22” For The Treatment Of Obesity
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a
Veru To Present At The GLP-1 Based Therapeutics Summit
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory
Establishment Labs Notes Presentation Of 4-Year Results From Motiva U.S. IDE Study At The Aesthetic Meeting 2024
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of
Limoneira’s Joint Venture With The Lewis Group Of Companies Announces The Closing For All Of Phase 2 At Harvest At Limoneira With National Home Builder Lennar
Phase 2 Closing Consists of 554 Homesites in Harvest; All Acquired by LennarJoint Venture Has Now Closed a Total of 1,261 Residential Homesite Sales at HarvestLimoneira Company (the "Company" or "Limoneira")
Akoya Biosciences And Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval For KR-HT5 In China To Support Next Generation Pathology Clinical Workflows
Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya